Phase I Study of Celecoxib with Concurrent Irinotecan, Cisplatin, and Radiation Therapy for Patients with Unresectable Locally Advanced Non-Small Cell Lung Cancer
暂无分享,去创建一个
Joe Y. Chang | Zhongxing Liao | James D. Cox | Xiong Wei | M. McAleer | R. Komaki | Z. Liao | J. Cox | L. Milas | P. Allen | M. Kies | G. Blumenschein | Xiong Wei | Ritsuko Komaki | Luka Milas | Pamela K. Allen | Merrill S. Kies | Mary Frances McAleer | Melenda Jeter | George R. Blumenschein | Michael S. O’Reilly | M. Jeter | M. O'Reilly | M. O’Reilly | J. Cox
[1] J. Daurès,et al. Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer: Groupe Lyon-Saint-Etienne d'Oncologie Thoracique-Groupe Français de Pneumo-Cancérologie NPC 95-01 Study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] Hyae-Young Kim,et al. A phase II study of irinotecan plus cisplatin for patients with advanced stage IIIB or IV NSCLC previously treated with nonplatinum‐based chemotherapy , 2006, Cancer.
[3] Thomas J. Smith,et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] Benjamin Movsas,et al. Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. , 2011, Journal of the National Cancer Institute.
[5] M. Shibuya,et al. Phase III randomized trial of docetaxel plus cisplatin versus vindesine plus cisplatin in patients with stage IV non-small-cell lung cancer: the Japanese Taxotere Lung Cancer Study Group. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] M. Slavik,et al. Phase I clinical trials. , 1977, National Cancer Institute monograph.
[7] D. Yankelevitz,et al. Celecoxib, a selective cyclo-oxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] M. Socinski,et al. Randomized phase II trial of docetaxel/irinotecan and gemcitabine/irinotecan with or without celecoxib in the second-line treatment of non-small-cell lung cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] K. Ulm,et al. Simultaneous chemoradiotherapy compared with radiotherapy alone after induction chemotherapy in inoperable stage IIIA or IIIB non-small-cell lung cancer: study CTRT99/97 by the Bronchial Carcinoma Therapy Group. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] J. Morrow,et al. A Phase II Study of Celecoxib in Combination with Paclitaxel, Carboplatin, and Radiotherapy for Patients with Inoperable Stage IIIA/B Non–Small Cell Lung Cancer , 2009, Clinical Cancer Research.
[11] Y. Yatabe,et al. Prognostic significance of elevated cyclooxygenase 2 expression in primary, resected lung adenocarcinomas. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[12] M. Socinski,et al. Third-Generation Chemotherapy Agents in the Treatment of Advanced Non-small Cell Lung Cancer: A Meta-Analysis , 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[13] R. Komaki,et al. Randomized trial of amifostine in locally advanced non-small-cell lung cancer patients receiving chemotherapy and hyperfractionated radiation: radiation therapy oncology group trial 98-01. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] M. Millenson,et al. Phase I Study of Radical Thoracic Radiation, Weekly Irinotecan, and Cisplatin in Locally Advanced Non-small Cell Lung Carcinoma , 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[15] A. Miller,et al. Reporting results of cancer treatment , 1981, Cancer.
[16] Joe Y. Chang,et al. A Phase I Clinical Trial of Thoracic Radiotherapy and Concurrent Celecoxib for Patients with Unfavorable Performance Status Inoperable/Unresectable Non–Small Cell Lung Cancer , 2005, Clinical Cancer Research.
[17] M. Gandelman. Celecoxib: a selective cyclooxygenase-2 inhibitor , 2003, Arthritis Research & Therapy.
[18] G. Nahler. dose escalation study , 2009 .
[19] Y. Nishimura,et al. Dose-escalation study of weekly irinotecan and daily carboplatin with concurrent thoracic radiotherapy for unresectable stage III non-small cell lung cancer , 2002, British Journal of Cancer.
[20] S. Kudoh,et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] Cancer Therapy Evaluation Program. Common Terminology Criteria for Adverse Events v3.0 (CTCAE) , 2003 .
[22] T. Kuriyama,et al. Phase I study of cisplatin and irinotecan combined with concurrent hyperfractionated accelerated thoracic radiotherapy for locally advanced non-small cell lung carcinoma , 2005, International Journal of Clinical Oncology.
[23] H. Groen,et al. Concomitant radio-chemotherapy based on platin compounds in patients with locally advanced non-small cell lung cancer (NSCLC): a meta-analysis of individual data from 1764 patients. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.
[24] B. Levine,et al. Cyclooxygenase-2 inhibition with celecoxib enhances antitumor efficacy and reduces diarrhea side effect of CPT-11. , 2002, Cancer research.
[25] M. Fukuoka,et al. Enhancement of Tumor Radio‐response by Irinotecan in Human Lung Tumor Xenografts , 1997, Japanese journal of cancer research : Gann.
[26] R. Komaki,et al. Improvement strategies for molecular targeting: Cyclooxygenase-2 inhibitors as radiosensitizers for non-small cell lung cancer. , 2004, Seminars in oncology.
[27] R. Govindan,et al. Definitive chemoradiation for the treatment of locally advanced non small-cell lung cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] S. Lippman,et al. Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[29] A. Jemal,et al. Global cancer statistics , 2011, CA: a cancer journal for clinicians.